Clinical Research
Please contact your provider to learn if you are eligible for any of our enrolling clinical trials.
Benefits to participants
- Learn more about your condition
- Get free study-related eye examinations, when appropriate
- Help others by assisting researchers to find better and more effective treatments
- Receive possible financial compensation for your time
Age-Related Macular Degeneration
ReNEW – SPIAM-301
Office: Teaneck
A Phase 3, Randomized, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects who have Dry Age-Related Macular Degeneration
Magnify – COG2201
Office: Edison
A Phase 2, Double-Masked, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants with Geographic Atrophy Secondary to Age-Related Macular Degeneration sponsored by Cognition Therapeutics, Inc.
Eyepoint Lugano EYP1901-301
Office: Toms River
A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept, in Subjects with Wet AMD
Diabetic Retinopathy
CRIMSON – 1436-0007
Office: Teaneck
A multicenter randomized, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy